Inhibition of nucleotide excision repair and sensitisation of cells to DNA cross-linking anticancer drugs by F 11782, a novel fluorinated epipodophylloid

被引:33
作者
Barret, JM [1 ]
Cadou, M [1 ]
Hill, BT [1 ]
机构
[1] Ctr Rech Pierre Fabre, Div Cancerol, F-81100 Castres, France
关键词
F; 11782; nucleotide excision repair; drug combination; catalytic topoisomerase inhibitor; DNA cross-linking agent;
D O I
10.1016/S0006-2952(01)00835-8
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
F 11782, or 2,3'-bis-pentafluorophenoxyacetyl-4,6'-ethylidene-beta-D-glucoside of 4-phosphate-4'-dimethylepipodophyllotoxin 2-N-methyl glucamine salt, a novel dual catalytic inhibitor of topoisomerases I and II, was identified as a potent inhibitor of nucleotide excision repair (NER) by screening procedures using the in vitro 3D (DNA damage detection) assay. F 11782 was then shown predominantly to inhibit the incision rather than the repair synthesis step, using two new methodologies derived from this 3D assay, effectively ruling out any inhibition of polymerases delta/epsilon. Moreover, data from two other in vitro assays showed an absence of any effect of F 11782 on: (i) the DNA damage binding of the XPA-RPA complex, and (ii) on SV40 large T-antigen helicase activity. Therefore, the inhibitory activity of F 11782 on NER may involve an inhibition of the ERCC1-XPF or XPG endonuclease activity. Moreover, inhibition of DNA repair by F 11782 was confirmed in human A549 cells by monitoring unscheduled DNA synthesis following mechlorethamine treatment. Such an inhibition provides an explanation for the highly synergistic cytotoxicity observed against cultured A549 lung tumour cells, when F 11782 was combined with cross-linking agents, such as cisplatin or mitomycin C. These results emphasise the unique mode of action of this novel molecule in inhibiting NER and provide a basis for its evaluation in clinical trials in combination with DNA cross-linking agents. (C) 2002 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:251 / 258
页数:8
相关论文
共 39 条
  • [1] Anthracycline antibiotic blockade of SV40 T antigen helicase action
    Bachur, NR
    Lun, L
    Sun, PM
    Trubey, CM
    Elliott, EE
    Egorin, MJ
    Malkas, L
    Hickey, R
    [J]. BIOCHEMICAL PHARMACOLOGY, 1998, 55 (07) : 1025 - 1034
  • [2] BACHUR NR, 1993, MOL PHARMACOL, V44, P1064
  • [3] Barret J.-M., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P307
  • [4] In vitro synergistic effects of vinflunine, a novel fluorinated vinca alkaloid, in combination with other anticancer drugs
    Barret, JM
    Etiévant, C
    Hill, BT
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2000, 45 (06) : 471 - 476
  • [5] DNA repair mechanisms associated with cellular resistance to antitumor drugs: potential novel targets
    Barret, JM
    Hill, BT
    [J]. ANTI-CANCER DRUGS, 1998, 9 (02) : 105 - 123
  • [6] Evaluation of DNA repair inhibition by antitumor or antibiotic drugs using a chemiluminescence microplate assay
    Barret, JM
    Salles, B
    Provot, C
    Hill, BT
    [J]. CARCINOGENESIS, 1997, 18 (12) : 2441 - 2445
  • [7] Bergman AM, 1996, CLIN CANCER RES, V2, P521
  • [8] DIFFERENT INHERITED LEVELS OF DNA REPAIR REPLICATION IN XERODERMA PIGMENTOSUM CELL STRAINS AFTER EXPOSURE TO ULTRAVIOLET IRRADIATION
    BOOTSMA, D
    MULDER, MP
    POT, F
    COHEN, JA
    [J]. MUTATION RESEARCH, 1970, 9 (05): : 507 - &
  • [9] CALSOU P, 1994, BIOCHEM BIOPH RES CO, V202, P4937
  • [10] QUANTITATIVE-ANALYSIS OF DOSE-EFFECT RELATIONSHIPS - THE COMBINED EFFECTS OF MULTIPLE-DRUGS OR ENZYME-INHIBITORS
    CHOU, TC
    TALALAY, P
    [J]. ADVANCES IN ENZYME REGULATION, 1984, 22 : 27 - 55